Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Gains from Investment Securities (2019 - 2025)

Avidity Biosciences' Gains from Investment Securities history spans 6 years, with the latest figure at -$57000.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$57000.0; the TTM value through Dec 2025 reached -$1.8 million, down 3.27%, while the annual FY2025 figure was -$140000.0, N/A changed from the prior year.
  • Gains from Investment Securities reached -$57000.0 in Q4 2025 per RNA's latest filing, up from -$1.7 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $12.1 million in Q4 2021 to a low of -$1.7 million in Q4 2023.
  • Average Gains from Investment Securities over 4 years is $3.6 million, with a median of $3.0 million recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: surged 7588.0% in 2021, then crashed 47.49% in 2022.
  • A 4-year view of Gains from Investment Securities shows it stood at $12.1 million in 2021, then crashed by 66.5% to $4.0 million in 2022, then plummeted by 143.09% to -$1.7 million in 2023, then skyrocketed by 96.73% to -$57000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNA's Gains from Investment Securities are -$57000.0 (Q4 2025), -$1.7 million (Q4 2023), and $4.0 million (Q3 2022).